Abstract
Objective: Polyethylene glycol (PEG) is common first-line therapy for urinary symptoms despite minimal evidence-based support. We performed a randomized, double-blind, placebo-controlled study of PEG for initial treatment of overactive bladder (OAB) symptoms in children. Patients and methods: Patients aged >3 years underwent baseline urinary symptom questionnaire (USQ, scored 0-16), bowel symptom questionnaire (scored 0-20) and abdominal X-ray (KUB). Patients were randomized to placebo/PEG regardless of parent's perception of constipation. After 1 month, patients completed follow-up questionnaires and KUB. Improvement was defined as decrease in USQ (ΔUSQ) ≥3 points. Secondary analyses compared urinary and bowel symptoms to KUB. Results: Of 138 enrolled patients, 71 (51.4%) completed 1 month of therapy. Analyses of those randomized to placebo vs. PEG and non-completers demonstrated similar demographics, baseline symptoms, and KUB. Patients treated with placebo and PEG both had significant improvement in USQ scores (p < 0.0001). Patients treated with placebo and PEG responded similarly to placebo (ΔUSQ 3.7 vs. 3.4, p = 0.773), with improvement in nearly half (48.5% PEG vs. 44.7% placebo). There was no correlation between KUB and urinary or bowel symptoms. Conclusions: Nearly 50% of patients with urinary urge symptoms treated with either placebo or PEG for 1 month had improvement in urinary symptoms. KUB did not correlate with baseline or follow-up urinary or bowel symptoms.
Original language | English (US) |
---|---|
Pages (from-to) | 597-604 |
Number of pages | 8 |
Journal | Journal of Pediatric Urology |
Volume | 9 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2013 |
Keywords
- Bowel and bladder dysfunction
- Constipation
- MiraLAX
- Overactive bladder
- Polyethylene glycol
- Urinary urgency
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Urology